Document -
Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR12 Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR12 with 8 weeks of treatment
-
License:
All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
- File format: .pdf